{
  "id": 16079239,
  "title": "Mundipharma Announces Further Phase III ReSPECT Results Presented as a Late-Breaking Oral Presentation at IDWeek 2026",
  "url": "https://urgent.news/2026/10/22/mundipharma-announces-further-phase-iii-respect-results-presented-as",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-22T17:07:51.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/pmn/business-wire-news-releases-pmn/mundipharma-announces-further-phase-iii-respect-results-presented-as-a-late-breaking-oral-presentation-at-idweek-2026"
  },
  "original_language": "en",
  "account": null,
  "summary": "For Trade and Medical Media Only CAMBRIDGE, England — Today Mundipharma announced additional results from the global Phase III ReSPECT clinical trial evaluating REZZAYO® (rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adult patients undergoing allogeneic haematopoietic stem cell transplantation (allo-HSCT). The Phase III findings were presented today as a late-breaking…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}